Page last updated: 2024-11-05

tranexamic acid and Thrombophlebitis

tranexamic acid has been researched along with Thrombophlebitis in 10 studies

Tranexamic Acid: Antifibrinolytic hemostatic used in severe hemorrhage.

Thrombophlebitis: Inflammation of a vein associated with a blood clot (THROMBUS).

Research Excerpts

ExcerptRelevanceReference
"Tranexamic acid (AMCA) is an inhibitor of fibrinolysis used to treat fibrinolytic bleeding (e."7.68Treatment with tranexamic acid during pregnancy, and the risk of thrombo-embolic complications. ( Astedt, B; Lindoff, C; Rybo, G, 1993)
" A combination of aprotinin with tranexamic acid may be effective in preventing or delaying rebleeding after rupture of an intracerebral aneurysm; the addition of aprotinin seems to decrease the incidence of delayed cerebral vasospasm and ischaemic complications which are sometimes noted when tranexamic acid alone is used."4.77Clinical application of inhibitors of fibrinolysis. ( Verstraete, M, 1985)
"Tranexamic acid (AMCA) is an inhibitor of fibrinolysis used to treat fibrinolytic bleeding (e."3.68Treatment with tranexamic acid during pregnancy, and the risk of thrombo-embolic complications. ( Astedt, B; Lindoff, C; Rybo, G, 1993)
"Case material included 25 patients with hemophilia (9 children and 16 adults) with high-responding inhibitors and 3 patients with acquired factor VIII inhibitors."2.70Relationship between factor VII activity and clinical efficacy of recombinant factor VIIa given by continuous infusion to patients with factor VIII inhibitors. ( Baudo, F; Gringeri, A; Morfini, M; Rocino, A; Santagostino, E; Scaraggi, FA, 2001)

Research

Studies (10)

TimeframeStudies, this research(%)All Research%
pre-19905 (50.00)18.7374
1990's2 (20.00)18.2507
2000's2 (20.00)29.6817
2010's1 (10.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bistervels, IM1
Scheres, LJJ1
Hamulyák, EN1
Middeldorp, S1
Martínez Rodríguez, E1
Mato, M1
Otero, J1
Ferri, JR1
Gonzálvez, A1
Torres, LM1
Gelmers, HJ1
Lindoff, C1
Rybo, G1
Astedt, B1
Hiippala, ST1
Strid, LJ1
Wennerstrand, MI1
Arvela, JV1
Niemelä, HM1
Mäntylä, SK1
Kuisma, RP1
Ylinen, JE1
Santagostino, E1
Morfini, M1
Rocino, A1
Baudo, F1
Scaraggi, FA1
Gringeri, A1
Hedlund, PO1
Verstraete, M1
Endo, Y2
Nishimura, S2
Miura, A2
Iwamoto, K1
Itoh, T1
Kuwayama, A1

Clinical Trials (7)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
The Effect of Local Tranexamic Acid on Post-operative Edema and Ecchymosis in Eyelid Surgery[NCT04951128]Phase 450 participants (Anticipated)Interventional2021-08-01Not yet recruiting
Tranexamic Acid in Surgery of Advanced Ovarian Cancer - a Prospective Randomized Double Blind Placebo Controlled Study[NCT00740116]Phase 4100 participants (Actual)Interventional2008-03-31Completed
Randomized Placebo Controlled Study Using Tranexamic Acid in Revision Total Hip Arthroplasty[NCT00375440]0 participants (Actual)Interventional2005-02-28Withdrawn (stopped due to Study halted prematurely as investigator left the institution.)
Prospective Randomised Trial Comparing Intraoperative Topical Quixil and Intravenous Tranexamic Acid, in Reduction of Blood Loss Following Primary Hip & Knee Joint Replacement Surgery.[NCT00378872]132 participants (Actual)Interventional2006-06-30Completed
The Impact of Topical Tranexamic Acid on Pre- and Post-operative Hemoglobin / Hematocrit in Isolated Operative Posterior Wall Acetabular Fractures: a Prospective, Randomized, Double-blinded, Multicenter Study[NCT05357079]Early Phase 198 participants (Anticipated)Interventional2017-08-25Recruiting
Intravenous Tranexamic Acid to Reduce Blood Loss in Reverse Total Shoulder Arthroplasty[NCT02043132]Phase 2/Phase 3116 participants (Actual)Interventional2013-09-30Completed
Efficacy in Controlling Bleeding Post-coronary Bypass Surgery Using Combination of Local Application of Tranexamic Acid and Intravenous Tranexamic Compared to Intravenous Tranexamic Acid Alone. A Randomized Controlled Trial[NCT01600599]40 participants (Actual)Interventional2011-01-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Median Number of Transfused Units of Red Blood Cells (RBC)

Median number of red blood cells transfused among those who received RBC transfusions (NCT00740116)
Timeframe: From start of operation to discharge from hospital, up to 5 weeks

Interventionunits (Median)
The Placebo Group2
The Tranexamic Acid Group2

Number of Patients Receiving Blood Transfusions

Total number of RBC-transfused women in each group (NCT00740116)
Timeframe: From start of operation to discharge from hospital, up to 5 weeks

Interventionparticipants (Number)
Tranexamic Group15
Placebo Group22

Number of Patients With Clinically or Radiologically Verified Thromboembolic Events Within 5 Weeks Postoperatively

Thromboembolic events including arterial thrombosis, muscle vein thrombosis, superficial and deep venous thrombosis. (NCT00740116)
Timeframe: From time of operation to 5 weeks postoperatively.

InterventionParticipants (Count of Participants)
Tranexamic Group2
Placebo Group5

Number of Units of Red Blood Cells (RBC) Transfused

Total number of red blood cells (RBC) transfused across all participants (NCT00740116)
Timeframe: From start of operation to discharge from hospital, up to 5 weeks

Interventionunits (Number)
Tranexamic Group38
Placebo Group53

Perioperative Bleeding Volume

Estimation of total blood loss was based on the estimation of the Hb balance method (Brecher, et al.1997) with the assumption that the body blood volume was normalised on the fifth postoperative day. The haemoglobin level was assessed preoperatively and on the fifth postoperative day. The predicted blood volume (PBV, l) was calculated according to the method described by Nadler et al. (1962), using body weight and height. The extravasation of haemoglobin was calculated taking into account allogenic transfused haemoglobin. Total blood loss perioperatively was related to the patient's preoperative haemoglobin value. Blood loss due to haematomas or a reoperation within the first five days after surgery was also considered. (NCT00740116)
Timeframe: From start of operation to discharge from hospital, up to 5 weeks

Interventionmilliliter (Median)
Tranexamic Group520
Placebo Group730

Number of Participants Experiencing Deep Vein Thrombosis

"The occurrence of the following systemic and surgical site complications within 6 weeks of surgery will be recorded. Data will be obtained from EMR and from patient at standard of care 2 week and 6 week follow-up appointment.~Deep venous thrombosis" (NCT02043132)
Timeframe: up to 6-weeks post-operatively

InterventionParticipants (Count of Participants)
Tranexamic Acid0
Normal Saline0

Number of Participants Experiencing Hematoma as a Surgical Site Complication

"The occurrence of the following systemic and surgical site complications within 6 weeks of surgery will be recorded. Data will be obtained from EMR and from patient at standard of care 2 week and 6 week follow-up appointment.~Hematoma" (NCT02043132)
Timeframe: up to 6-weeks post-operatively

InterventionParticipants (Count of Participants)
Tranexamic Acid0
Normal Saline0

Number of Participants Experiencing Infection as a Surgical Site Complication

"The occurrence of the following systemic and surgical site complications within 6 weeks of surgery will be recorded. Data will be obtained from EMR and from patient at standard of care 2 week and 6 week follow-up appointment.~Infection" (NCT02043132)
Timeframe: up to 6-weeks post-operatively

InterventionParticipants (Count of Participants)
Tranexamic Acid0
Normal Saline0

Number of Participants Experiencing Myocardial Infarction

"The occurrence of the following systemic and surgical site complications within 6 weeks of surgery will be recorded. Data will be obtained from EMR and from patient at standard of care 2 week and 6 week follow-up appointment.~Myocardial infarction" (NCT02043132)
Timeframe: up to 6-weeks post-operatively

InterventionParticipants (Count of Participants)
Tranexamic Acid0
Normal Saline1

Number of Participants Experiencing Pulmonary Embolism

"The occurrence of the following systemic and surgical site complications within 6 weeks of surgery will be recorded. Data will be obtained from EMR and from patient at standard of care 2 week and 6 week follow-up appointment.~Pulmonary Embolism" (NCT02043132)
Timeframe: up to 6-weeks post-operatively

InterventionParticipants (Count of Participants)
Tranexamic Acid0
Normal Saline0

Total Blood Loss

Total Blood Loss as calculated according to method as described by Good et al. Total Blood Loss (mL) = 1000 X Hb(loss)/Hb(initial) (NCT02043132)
Timeframe: Preoperative through Postoperative Days 1 and 2

InterventionTotal Blood Loss (mL) (Mean)
Tranexamic Acid1122.4
Normal Saline1472

Total Drain Output

Total Drain Output as measured postoperatively 0-48 hours (NCT02043132)
Timeframe: 0-48 hours postoperatively

InterventionmL (Mean)
Tranexamic Acid221
Normal Saline372

Total Hemoglobin Loss

Total hemoglobin loss estimated using the formula for total blood volume described by Nadler et al Hb(loss) = blood volume (L) x [Hb(initial)(g/L) - Hb(final)(g/L)] + Hb(transfused) (NCT02043132)
Timeframe: Preoperative through Postoperative Days 1 and 2

Interventiong (Mean)
Tranexamic Acid154.6
Normal Saline200.1

Reviews

2 reviews available for tranexamic acid and Thrombophlebitis

ArticleYear
Sex matters: Practice 5P's when treating young women with venous thromboembolism.
    Journal of thrombosis and haemostasis : JTH, 2019, Volume: 17, Issue:9

    Topics: Adult; Anticoagulants; Contraceptives, Oral, Combined; Disease Susceptibility; Female; Heparin, Low-

2019
Clinical application of inhibitors of fibrinolysis.
    Drugs, 1985, Volume: 29, Issue:3

    Topics: 4-Aminobenzoic Acid; Aminocaproic Acid; Angioedema; Antifibrinolytic Agents; Aprotinin; Blood Preser

1985

Trials

4 trials available for tranexamic acid and Thrombophlebitis

ArticleYear
Prevention of recurrence of spontaneous subarachnoid haemorrhage by tranexamic acid.
    Acta neurochirurgica, 1980, Volume: 52, Issue:1-2

    Topics: Adult; Aged; Cyclohexanecarboxylic Acids; Female; Humans; Male; Middle Aged; Recurrence; Subarachnoi

1980
Tranexamic acid radically decreases blood loss and transfusions associated with total knee arthroplasty.
    Anesthesia and analgesia, 1997, Volume: 84, Issue:4

    Topics: Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Double-Blind Method; Female;

1997
Tranexamic acid radically decreases blood loss and transfusions associated with total knee arthroplasty.
    Anesthesia and analgesia, 1997, Volume: 84, Issue:4

    Topics: Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Double-Blind Method; Female;

1997
Tranexamic acid radically decreases blood loss and transfusions associated with total knee arthroplasty.
    Anesthesia and analgesia, 1997, Volume: 84, Issue:4

    Topics: Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Double-Blind Method; Female;

1997
Tranexamic acid radically decreases blood loss and transfusions associated with total knee arthroplasty.
    Anesthesia and analgesia, 1997, Volume: 84, Issue:4

    Topics: Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Double-Blind Method; Female;

1997
Tranexamic acid radically decreases blood loss and transfusions associated with total knee arthroplasty.
    Anesthesia and analgesia, 1997, Volume: 84, Issue:4

    Topics: Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Double-Blind Method; Female;

1997
Tranexamic acid radically decreases blood loss and transfusions associated with total knee arthroplasty.
    Anesthesia and analgesia, 1997, Volume: 84, Issue:4

    Topics: Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Double-Blind Method; Female;

1997
Tranexamic acid radically decreases blood loss and transfusions associated with total knee arthroplasty.
    Anesthesia and analgesia, 1997, Volume: 84, Issue:4

    Topics: Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Double-Blind Method; Female;

1997
Tranexamic acid radically decreases blood loss and transfusions associated with total knee arthroplasty.
    Anesthesia and analgesia, 1997, Volume: 84, Issue:4

    Topics: Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Double-Blind Method; Female;

1997
Tranexamic acid radically decreases blood loss and transfusions associated with total knee arthroplasty.
    Anesthesia and analgesia, 1997, Volume: 84, Issue:4

    Topics: Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Double-Blind Method; Female;

1997
Tranexamic acid radically decreases blood loss and transfusions associated with total knee arthroplasty.
    Anesthesia and analgesia, 1997, Volume: 84, Issue:4

    Topics: Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Double-Blind Method; Female;

1997
Tranexamic acid radically decreases blood loss and transfusions associated with total knee arthroplasty.
    Anesthesia and analgesia, 1997, Volume: 84, Issue:4

    Topics: Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Double-Blind Method; Female;

1997
Tranexamic acid radically decreases blood loss and transfusions associated with total knee arthroplasty.
    Anesthesia and analgesia, 1997, Volume: 84, Issue:4

    Topics: Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Double-Blind Method; Female;

1997
Tranexamic acid radically decreases blood loss and transfusions associated with total knee arthroplasty.
    Anesthesia and analgesia, 1997, Volume: 84, Issue:4

    Topics: Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Double-Blind Method; Female;

1997
Tranexamic acid radically decreases blood loss and transfusions associated with total knee arthroplasty.
    Anesthesia and analgesia, 1997, Volume: 84, Issue:4

    Topics: Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Double-Blind Method; Female;

1997
Tranexamic acid radically decreases blood loss and transfusions associated with total knee arthroplasty.
    Anesthesia and analgesia, 1997, Volume: 84, Issue:4

    Topics: Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Double-Blind Method; Female;

1997
Tranexamic acid radically decreases blood loss and transfusions associated with total knee arthroplasty.
    Anesthesia and analgesia, 1997, Volume: 84, Issue:4

    Topics: Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Double-Blind Method; Female;

1997
Relationship between factor VII activity and clinical efficacy of recombinant factor VIIa given by continuous infusion to patients with factor VIII inhibitors.
    Thrombosis and haemostasis, 2001, Volume: 86, Issue:4

    Topics: Adult; Antigens; Blood Loss, Surgical; Child; Child, Preschool; Drug Administration Schedule; Electi

2001
Postoperative venous thrombosis in benign prostatic disease. A study of 316 patients, using the 125I-fibrinogen uptake test.
    Scandinavian journal of urology and nephrology, 1975, Issue:27 suppl

    Topics: Acute Disease; Aged; Clinical Trials as Topic; Dextrans; Fibrinogen; Heparin; Humans; Male; Middle A

1975

Other Studies

4 other studies available for tranexamic acid and Thrombophlebitis

ArticleYear
[Hemostatic drugs in a patient with antiphospholipid syndrome and clinically significant perioperative bleeding].
    Revista espanola de anestesiologia y reanimacion, 2006, Volume: 53, Issue:3

    Topics: Adult; Aminocaproic Acid; Antiphospholipid Syndrome; Aprotinin; Blood Coagulation Tests; Blood Loss,

2006
Treatment with tranexamic acid during pregnancy, and the risk of thrombo-embolic complications.
    Thrombosis and haemostasis, 1993, Aug-02, Volume: 70, Issue:2

    Topics: Abruptio Placentae; Case-Control Studies; Cesarean Section; Female; Hemorrhage; Humans; Incidence; P

1993
Treatment with tranexamic acid during pregnancy, and the risk of thrombo-embolic complications.
    Thrombosis and haemostasis, 1993, Aug-02, Volume: 70, Issue:2

    Topics: Abruptio Placentae; Case-Control Studies; Cesarean Section; Female; Hemorrhage; Humans; Incidence; P

1993
Treatment with tranexamic acid during pregnancy, and the risk of thrombo-embolic complications.
    Thrombosis and haemostasis, 1993, Aug-02, Volume: 70, Issue:2

    Topics: Abruptio Placentae; Case-Control Studies; Cesarean Section; Female; Hemorrhage; Humans; Incidence; P

1993
Treatment with tranexamic acid during pregnancy, and the risk of thrombo-embolic complications.
    Thrombosis and haemostasis, 1993, Aug-02, Volume: 70, Issue:2

    Topics: Abruptio Placentae; Case-Control Studies; Cesarean Section; Female; Hemorrhage; Humans; Incidence; P

1993
Deep-vein thrombosis induced by tranexamic acid in idiopathic thrombocytopenic purpura.
    JAMA, 1988, Jun-24, Volume: 259, Issue:24

    Topics: Aged; Aged, 80 and over; Cyclohexanecarboxylic Acids; Humans; Male; Purpura, Thrombocytopenic; Throm

1988
[Idiopathic thrombocytopenic purpura, associated with deep vein thrombosis induced by tranexamic acid].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 1988, Volume: 29, Issue:2

    Topics: Aged; Aged, 80 and over; Cyclohexanecarboxylic Acids; Fibrinolysis; Humans; Male; Purpura, Thrombocy

1988